Methylphenidate fails to improve gait and muscle tone in patients with sporadic and hereditary spastic paraplegia.
Identifieur interne : 002C37 ( PubMed/Checkpoint ); précédent : 002C36; suivant : 002C38Methylphenidate fails to improve gait and muscle tone in patients with sporadic and hereditary spastic paraplegia.
Auteurs : Stephan Klebe [Allemagne] ; Günther Deuschl ; Henning StolzeSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- Adenosine Triphosphatases (genetics), Adult, Central Nervous System Stimulants (adverse effects), Central Nervous System Stimulants (therapeutic use), Chromosomes, Human, Pair 2, Female, Follow-Up Studies, Gait (drug effects), Humans, Male, Methylphenidate (adverse effects), Methylphenidate (therapeutic use), Middle Aged, Muscle Tonus (drug effects), Paraplegia (drug therapy), Signal Processing, Computer-Assisted, Spastic Paraplegia, Hereditary (drug therapy), Treatment Failure.
- MESH :
- chemical , adverse effects : Central Nervous System Stimulants, Methylphenidate.
- chemical , genetics : Adenosine Triphosphatases.
- chemical , therapeutic use : Central Nervous System Stimulants, Methylphenidate.
- drug effects : Gait, Muscle Tonus.
- drug therapy : Paraplegia, Spastic Paraplegia, Hereditary.
- Adult, Chromosomes, Human, Pair 2, Female, Follow-Up Studies, Humans, Male, Middle Aged, Signal Processing, Computer-Assisted, Treatment Failure.
Abstract
Based on its action on multiple neurotransmitters, including dopamine, methylphenidate (MPH) is of growing interest as a possible treatment option for several movement disorders. Of special interest are diseases that share gait disturbance and cognitive decline. Based on a single case observation in a patient with hereditary spastic spinal paraplegia (HSP) in which gait was improved with MPH, we performed an open-label study with a longitudinal follow-up in 22 patients with HSP and its sporadic form (SSP). The patients were treated for 6 months with 60 mg of MPH per day. Computerized gait analysis and different scores were performed at baseline, after 6 weeks, and after 6 months of treatment. Although at 6 weeks, the gait velocity was somewhat improved, the drug failed to show any effect on other gait parameters and had no beneficial effect at all after 6 months. Although MPH is of interest for several movement disorders, our study did not show a beneficial effect.
DOI: 10.1002/mds.20973
PubMed: 16705687
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:16705687Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Methylphenidate fails to improve gait and muscle tone in patients with sporadic and hereditary spastic paraplegia.</title>
<author><name sortKey="Klebe, Stephan" sort="Klebe, Stephan" uniqKey="Klebe S" first="Stephan" last="Klebe">Stephan Klebe</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Christian-Albrechts-Universität zu Kiel, Kiel</wicri:regionArea>
<placeName><region type="land" nuts="2">Schleswig-Holstein</region>
<settlement type="city">Kiel</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Deuschl, Gunther" sort="Deuschl, Gunther" uniqKey="Deuschl G" first="Günther" last="Deuschl">Günther Deuschl</name>
</author>
<author><name sortKey="Stolze, Henning" sort="Stolze, Henning" uniqKey="Stolze H" first="Henning" last="Stolze">Henning Stolze</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="doi">10.1002/mds.20973</idno>
<idno type="RBID">pubmed:16705687</idno>
<idno type="pmid">16705687</idno>
<idno type="wicri:Area/PubMed/Corpus">002C27</idno>
<idno type="wicri:Area/PubMed/Curation">002C27</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002C37</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Methylphenidate fails to improve gait and muscle tone in patients with sporadic and hereditary spastic paraplegia.</title>
<author><name sortKey="Klebe, Stephan" sort="Klebe, Stephan" uniqKey="Klebe S" first="Stephan" last="Klebe">Stephan Klebe</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Christian-Albrechts-Universität zu Kiel, Kiel</wicri:regionArea>
<placeName><region type="land" nuts="2">Schleswig-Holstein</region>
<settlement type="city">Kiel</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Deuschl, Gunther" sort="Deuschl, Gunther" uniqKey="Deuschl G" first="Günther" last="Deuschl">Günther Deuschl</name>
</author>
<author><name sortKey="Stolze, Henning" sort="Stolze, Henning" uniqKey="Stolze H" first="Henning" last="Stolze">Henning Stolze</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Triphosphatases (genetics)</term>
<term>Adult</term>
<term>Central Nervous System Stimulants (adverse effects)</term>
<term>Central Nervous System Stimulants (therapeutic use)</term>
<term>Chromosomes, Human, Pair 2</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Gait (drug effects)</term>
<term>Humans</term>
<term>Male</term>
<term>Methylphenidate (adverse effects)</term>
<term>Methylphenidate (therapeutic use)</term>
<term>Middle Aged</term>
<term>Muscle Tonus (drug effects)</term>
<term>Paraplegia (drug therapy)</term>
<term>Signal Processing, Computer-Assisted</term>
<term>Spastic Paraplegia, Hereditary (drug therapy)</term>
<term>Treatment Failure</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Central Nervous System Stimulants</term>
<term>Methylphenidate</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Adenosine Triphosphatases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Central Nervous System Stimulants</term>
<term>Methylphenidate</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Gait</term>
<term>Muscle Tonus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Paraplegia</term>
<term>Spastic Paraplegia, Hereditary</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Chromosomes, Human, Pair 2</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Signal Processing, Computer-Assisted</term>
<term>Treatment Failure</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Based on its action on multiple neurotransmitters, including dopamine, methylphenidate (MPH) is of growing interest as a possible treatment option for several movement disorders. Of special interest are diseases that share gait disturbance and cognitive decline. Based on a single case observation in a patient with hereditary spastic spinal paraplegia (HSP) in which gait was improved with MPH, we performed an open-label study with a longitudinal follow-up in 22 patients with HSP and its sporadic form (SSP). The patients were treated for 6 months with 60 mg of MPH per day. Computerized gait analysis and different scores were performed at baseline, after 6 weeks, and after 6 months of treatment. Although at 6 weeks, the gait velocity was somewhat improved, the drug failed to show any effect on other gait parameters and had no beneficial effect at all after 6 months. Although MPH is of interest for several movement disorders, our study did not show a beneficial effect.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16705687</PMID>
<DateCreated><Year>2006</Year>
<Month>09</Month>
<Day>27</Day>
</DateCreated>
<DateCompleted><Year>2007</Year>
<Month>02</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>21</Volume>
<Issue>9</Issue>
<PubDate><Year>2006</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Methylphenidate fails to improve gait and muscle tone in patients with sporadic and hereditary spastic paraplegia.</ArticleTitle>
<Pagination><MedlinePgn>1468-71</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Based on its action on multiple neurotransmitters, including dopamine, methylphenidate (MPH) is of growing interest as a possible treatment option for several movement disorders. Of special interest are diseases that share gait disturbance and cognitive decline. Based on a single case observation in a patient with hereditary spastic spinal paraplegia (HSP) in which gait was improved with MPH, we performed an open-label study with a longitudinal follow-up in 22 patients with HSP and its sporadic form (SSP). The patients were treated for 6 months with 60 mg of MPH per day. Computerized gait analysis and different scores were performed at baseline, after 6 weeks, and after 6 months of treatment. Although at 6 weeks, the gait velocity was somewhat improved, the drug failed to show any effect on other gait parameters and had no beneficial effect at all after 6 months. Although MPH is of interest for several movement disorders, our study did not show a beneficial effect.</AbstractText>
<CopyrightInformation>(c) 2006 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klebe</LastName>
<ForeName>Stephan</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Deuschl</LastName>
<ForeName>Günther</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Stolze</LastName>
<ForeName>Henning</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>207ZZ9QZ49</RegistryNumber>
<NameOfSubstance UI="D008774">Methylphenidate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber>
<NameOfSubstance UI="D000251">Adenosine Triphosphatases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber>
<NameOfSubstance UI="C400283">SPAST protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000251">Adenosine Triphosphatases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000697">Central Nervous System Stimulants</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D002889">Chromosomes, Human, Pair 2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005684">Gait</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008774">Methylphenidate</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009129">Muscle Tonus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010264">Paraplegia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D012815">Signal Processing, Computer-Assisted</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D015419">Spastic Paraplegia, Hereditary</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D017211">Treatment Failure</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>5</Month>
<Day>18</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2007</Year>
<Month>2</Month>
<Day>3</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>5</Month>
<Day>18</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.20973</ArticleId>
<ArticleId IdType="pubmed">16705687</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
</country>
<region><li>Schleswig-Holstein</li>
</region>
<settlement><li>Kiel</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Deuschl, Gunther" sort="Deuschl, Gunther" uniqKey="Deuschl G" first="Günther" last="Deuschl">Günther Deuschl</name>
<name sortKey="Stolze, Henning" sort="Stolze, Henning" uniqKey="Stolze H" first="Henning" last="Stolze">Henning Stolze</name>
</noCountry>
<country name="Allemagne"><region name="Schleswig-Holstein"><name sortKey="Klebe, Stephan" sort="Klebe, Stephan" uniqKey="Klebe S" first="Stephan" last="Klebe">Stephan Klebe</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C37 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002C37 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:16705687 |texte= Methylphenidate fails to improve gait and muscle tone in patients with sporadic and hereditary spastic paraplegia. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:16705687" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |